You are here
Canadian News
 |
Monday, January 25, 2021 |
Servier obtains Top Employer Europe 2021 certification |
 |
 |
Wednesday, January 20, 2021 |
Servier Group – Financial Year 2019/2020 Financial results and R&D strategy and pipeline |
|
 |
Monday, December 14, 2020 |
The Servier Group opens a worldwide Artificial Intelligence Hub in Montreal, in partnership with Centech |
|
 |
Monday, August 31, 2020 |
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and intracranial hemorrhage (ICH) rates in frail and elderly AF patients on LIXIANA® (edoxaban) during routine clinical care |
|
 |
Thursday, June 4, 2020 |
Servier completes the acquisition of Symphogen
|
|
 |
Thursday, April 2, 2020 |
Servier partners with Innovative Medicines Canada Members to Donate 100,000 Masks to Help Protect Front-Line Healthcare Workers Battling COVID-19 |
|
 |
Wednesday, April 1, 2020 |
Coronavirus Information (COVID-19) |
|
 |
Thursday, March 5, 2020 |
Servier Group – Financial Year 2018/19 : Financial results and R&D pipeline |
|
 |
Wednesday, September 4, 2019 |
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NonValvular Atrial Fibrillation Patients |
|
 |
Tuesday, September 3, 2019 |
Servier Canada announces Positive Results of the ENTRUSTAF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation |
|
 |
Wednesday, March 13, 2019 |
LIXIANA® (edoxaban) now reimbursed by the Régie de l’assurance maladie du Québec for patients with atrial fibrillation or venous thromboembolism |
|
 |
Monday, November 5, 2018 |
LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure |
|
 |
Thursday, November 1, 2018 |
Servier Receives Health Canada Approval of FOLOTYN® for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma |
|
 |
Thursday, September 27, 2018 |
LANCORA™ (ivabradine) now covered by the Régie de l’assurance maladie du Quebec for patients suffering from heart failure |
|
 |
Tuesday, September 11, 2018 |
Servier Canada Announces the Availability of ZEVALIN®, the Only Single-course Chemo-free Treatment Regimen for the Treatment of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma. |
|
 |
Wednesday, September 5, 2018 |
Servier Canada announces the Expansion of its Oncology Portfolio through the acquisition by Servier group of Shire’s oncology branch |
|
 |
Tuesday, June 19, 2018 |
Servier Canada, in collaboration with Hypertension Canada, launches the GETDOWNBP Hypertension Management mobile App |
|
 |
Monday, January 15, 2018 |
Servier Canada and the New Brunswick Health Research Foundation announce the creation of the Servier-New Brunswick Cardiac Health Improvement Fund (CHIF) |
|
 |
Wednesday, January 10, 2018 |
Servier and Treventis begin strategic research partnership in neurodegenerative diseases |
|
 |
Friday, December 15, 2017 |
Once-Daily Oral Anticoagulant LIXIANA(edoxaban) met Primary Endpoint in Investigational Hokusai-VTE CANCER Study |
|
 |
Thursday, November 23, 2017 |
Servier Canada establishes a new partnership with CQDM to fund a diabetes research project. |
|
 |
Friday, November 10, 2017 |
Servier Canada announces the launch of VENIXXA, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids. |
|
 |
Tuesday, June 20, 2017 |
Servier Canada, Government of Alberta, and the University Hospital Foundation announce the formation of the Servier Alberta Innovation in Health Fund (SAIHF) |
|
 |
Wednesday, May 3, 2017 |
ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban)
in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic
Valve Implantation was initiated |
|
 |
Monday, April 3, 2017 |
SERVIER CANADA Announces New Toronto Offices |
|
 |
Friday, March 31, 2017 |
ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation was initiated. |
|
 |
Tuesday, February 7, 2017 |
Servier announces an increase in turnover for 2015-2016. Growth bolstered by strong international performance |
|
 |
Tuesday, January 10, 2017 |
Health Canada approves new heart failure treatment LANCORA™ to reduce mortality and hospitalizations |
|
 |
Wednesday, December 7, 2016 |
GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis |
|
 |
Wednesday, November 9, 2016 |
Once-Daily Anticoagulant LIXIANA® (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism |
|
 |
Thursday, October 20, 2016 |
New compound shows promise in treating multiple human cancers |
|
| Monday, September 26, 2016 |
$21 Million Investment in Québec Biotech Start-up to Develop a Treatment for Venous Lower Limb Ulcers |
|
|
 |
Thursday, September 1, 2016 |
Amgen and Servier extend omecamtiv mecarbil collaboration in chronic heart failure |
|
 |
Monday, June 27, 2016 |
Servier Canada is pleased to announce the signing of a strategic agreement with Daiichi Sankyo Co., Limited |
|
 |
Friday, January 29, 2016 |
Viacoram now approved in Canada as a new first line treatment in hypertension |
|
 |
Tuesday, January 12, 2016 |
Spectrum Pharmaceuticals signs a strategic partnership with Servier Canada |
|
 |
Thursday, November 19, 2015 |
Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19 |
|
 |
Thursday, November 13, 2014 |
INTARCIA and SERVIER sign EX-U.S. partnership for ITCA 650 in diabetes |
|
 |
Friday, October 10, 2014 |
|
|
 |
Friday, September 19, 2014 |
SERVIER and CTI BIOPHARMA announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI |
|
 |
Friday, April 18, 2014 |
Servier Research Group announces the death of President-Founder Dr. Jacques Servier |
|
 |
Wednesday, April 16, 2014 |
Servier: one of France’s most remarkable industrial undertakings |
|
 |
Friday, February 14, 2014 |
Servier Canada invests $10M in two research projects supported by the Partnership Fund for an Innovative, Healthy Quebec |
|